ONK strengthens cell therapy manufacturing capabilities

By The Science Advisory Board staff writers

March 18, 2021 -- ONK Therapeutics has entered into a license agreement with the U.S. National Institutes of Health (NIH) to gain rights to make and use clinically validated good manufacturing practice (GMP)-grade feeder cell lines that will enable robust natural killer (NK) cell expansion to support the scale up of the company's manufacturing process.

The proprietary, GMP-grade Epstein Barr Virus-transformed lymphoblastoid cell line has been proven to expand NK cells as part of a clinical trial conducted at the NIH. The feeder layer enables expansion of up to 1,000-fold over a period of two to three weeks. The expansion produces a stable and consistent NK cell population that can be subsequently genetically modified and further expanded on a batch scale to support clinical trials of ONK's NK cell therapy candidates.

The company's proprietary dual-targeted NK cell platform expresses both a chimeric antigen receptor (CAR) targeting a known tumor antigen and a tumor necrosis factor (TNF)-related apoptosis-inducing ligand variant (TRAILv) targeting the death receptor pathway (e.g., DR4 or DR5).

In conjunction with ONK's recent license with Anthony Nolan Cell & Gene Therapy Services, the company should provide the critical starting materials for its off-the-shelf cell therapy manufacturing process to support researchers and process development work.

ONK licenses 3 NK cell therapy products
ONK Therapeutics has signed three licensing agreements for natural killer (NK) cell therapy products.
Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...

Copyright © 2021 scienceboard.net


Conferences
Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter